Clinical Trials Using Capmatinib
Clinical trials are research studies that involve people. The clinical trials on this list are studying Capmatinib. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer
A phase II study to evaluate antitumor activity of oral cMET inhibitor INC280 in adult patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC) as measured by overall response rate (ORR). The study will also evaluate safety and pharmacokinetics of INC280.
Location: 10 locations
Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
The primary purpose of this study is to evaluate the efficacy of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma
Location: 7 locations
Capmatinib in Treating Patients with Recurrent or Advanced Non-small Cell Lung Cancer with MET Exon 14 Alterations or MET Amplification Previously Treated with MET Inhibitor Therapy
This phase II trial studies how well capmatinib works in treating patients with non-small cell lung cancer with MET exon 14 alterations or MET amplification that has previously been treated with MET inhibitor therapy and has come back or spread to other places in the body. Capmatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Location: 2 locations
A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
Background: - Papillary RCC is the second most common histologic subtype of kidney cancer, accounting for approximately 10-15% of cases - Type 1 papillary RCC occurs in both sporadic and hereditary forms, which are histologically identical. Non-familial type 1 papillary RCC can present as both solitary renal tumors and as bilateral, multifocal disease - There are no standard agents of proven efficacy for patients with advanced papillary RCC. - Patients with disease localized to the kidney are managed surgically while patients with advanced / unresectable disease are usually managed in the community with VEGF pathway antagonists or mTOR inhibitors. - Activating mutations of MET were identified in the germline of affected HPRC patients, who have a predilection for the development of bilateral, multifocal type 1 papillary RCC. Somatic MET mutations have been found in a subset of patients with non-inherited, sporadic papillary renal carcinoma - The investigational agent INC280 is a selective MET inhibitor lacking activity against the VEGF pathway - This is a proof-of-concept study using INC280 in patients with papillary RCC to test the idea that effectively blocking the HGF / MET pathway will lead to clinical activity in patients with papillary renal cell cancer Objectives: Primary Objective: -To determine the overall response rate (RECIST 1.1) in patients with papillary renal cell carcinoma treated with single agent INC280 Eligibility: - Diagnosis of hereditary papillary renal carcinoma (HPRC) or sporadic papillary renal cell carcinoma (RCC) - Patients with bilateral multifocal disease can have tumors localized to the kidney or have metastatic disease - Patients with sporadic papillary RCC (but without multifocal disease) should have advanced disease that is considered unresectable - ECOG 0-2 - Measurable disease - Adequate organ function - No active brain metastases - Prior therapy - No more than 3 prior lines of systemic therapy - Prior therapy with a MET inhibitor is allowed as long as the patient has not had progressive disease while receiving the agent Design: - This is a phase 2 single center non-randomized trial. - The study will be conducted using a Simon 2 stage minimax design. Initially 13 evaluable subjects will be recruited. If there are no responses to therapy, the study will be terminated. If there is at least 1 response an additional 7 evaluable subjects will be accrued. - The two-stage minimax design is based on assuming an ineffective response rate of 5% and a targeted effective response rate of 25%. We also assume that the probability of accepting an ineffective treatment and the probability of rejecting an effective treatment are each 10%. - Subjects will be dosed orally at a starting dose of 600 mg twice daily. - The overall response rate (complete response + partial response) will be determined.
Location: 2 locations
Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
This is a Phase Ib, open label, dose escalation study of spartalizumab + LAG525 in combination with NIR178, capmatinib, MCS110, or canakinumab, followed by a dose expansion in adult patients with advanced or metastatic TNBC. During the dose-escalation part of each treatment arm, patients will be treated with fixed doses of spartalizumab + LAG525 in combination with partner investigational drugs to be escalated until the MTD is reached or a lower RDE is established: NIR178, capmatinib, MCS110, or canakinumab. It is anticipated that other partner study drugs may be added in the future by protocol amendment. After the determination of the MTD / RDE for a particular treatment arm, dose expansion may begin in that arm in order to further assess safety, tolerability, PK / PD, and anti-tumor activity of each combination at the MTD / RDE. Dose expansion arms may initiate only after consideration by the Investigators and Novartis of all available toxicity information, the assessment of risk to future patients from the BLRM, and the available PK, preliminary efficacy, and PD information. There is no requirement for dose-escalation treatment arms reaching an MTD / RDE to proceed to dose expansion.
Location: NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center, New York, New York
Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer
This is a clinical research study and the purpose of the study is to learn whether the combination of the drugs capmatinib plus spartalizumab helps to control lung cancer better compared to a single agent chemotherapy (docetaxel) and whether it is safe when given to patients with NSCLC. Capmatinib is an oral drug that is called a "targeted" medicine: this means it targets particular processes, which may not be working properly in the cancer cells in your body (called dysregulation) and which may be causing your disease. Spartalizumab is an antibody (a kind of protein that binds to a specific "target" protein). By blocking its "target" protein, called PD-1, spartalizumab may increase the activity of a certain type of cells in your immune system, which may reduce the growth of your tumor. Docetaxel is a standard chemotherapy medicine commonly used to treat your type of lung cancer. This standard, anti-cancer medicine is a cytotoxic chemotherapy that is being compared with capmatinib and spartalizumab. The reason for this study is to find out which of these two treatments (combination of capmatinib plus spartalizumab OR docetaxel alone) helps to control lung cancer better.
Location: Moffitt Cancer Center, Tampa, Florida
Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer
To determine the efficacy and safety of Nivolumab in combination with EGF816 and of Nivolumab in combination with INC280 in previously treated NSCLC patients
Location: 2 locations